Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RAD301 in Healthy Volunteers and Patients With Solid Tumors
NCT05799274Phase 1Active, not recruiting
- Sponsor
- Radiopharm Theranostics
- Start
- Nov 2023
- Primary completion
- Sep 2026
- Modality
- Peptide-Drug Conjugates
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of 68Ga-RAD301 in pancreatic ductal adenocarcinoma (PDAC), non-small cell lung cancer (NSCLC), Esophageal Squamous Cell Carcinoma (ESCC) and 3 more, sponsored by Radiopharm Theranostics. Primary endpoints: Radiation dosimetry of RAD301 at 6 hours and Safety and tolerability of RAD301 at 4 weeks. Started Nov 2023; status: active, not recruiting.
02
Drugs
68Ga-RAD301
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)non-small cell lung cancer (NSCLC)Esophageal Squamous Cell Carcinoma (ESCC)Cervical Cancer (CC)endometrial cancer (EC)
Beyond the preview
Go deeper on NCT05799274.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05799274.